Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Gastrointestinal 1Breast 1

Conditions

Prostatic Neoplasms 13Pancreatic Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Sarcoma, Ewing 2Ovarian Neoplasms 2Neoplasm Metastasis 2Colorectal Neoplasms 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Prostatic Diseases 1Prostate Cancer Metastatic 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasms 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Kidney Neoplasms 1Hepatoblastoma 1Fanconi Anemia, Complementation Group D1 1Carcinoma, Transitional Cell 1Carcinoma, Ovarian Epithelial 1Adenocarcinoma 1

Interventions

Sunitinib 145Nivolumab 144pembrolizumab 132Sorafenib 84Bevacizumab 77Everolimus 74cabozantinib 71pazopanib 65Axitinib 65Ipilimumab 62aldesleukin 52Magnetic Resonance Spectroscopy 45Cyclophosphamide 40Interleukin-2 38lenvatinib 37Specimen Handling 36Radiosurgery 36Interferon-alpha 32atezolizumab 30temsirolimus 27belzutifan 24Gemcitabine 23fludarabine phosphate 22avelumab 22Radiotherapy 19Interferon alpha-2 19Biopsy 18fludarabine 17durvalumab 17Nephrectomy 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × talazoparib × Genitourinary × Clear all
NCT04337970 2025-05-28

Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
23 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04068831 2024-12-27

Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
18 enrolled 9 charts
Genitourinary

Carcinoma, Renal Cell

NCT03875313 2022-02-17

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Calithera Biosciences, Inc

Phase 1/2 Terminated
33 enrolled 14 charts
BreastGastrointestinalGenitourinary

Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡